This CE program will highlight recent scientific advances in the treatment and management of patients with polycythemia vera (PV) presented at the American Society of Hematology 59th Annual Meeting & Exposition in Atlanta, Georgia. The three expert faculty will review the science and diagnostic criteria of PV, focusing on the treatment of the resistant/intolerant patient population. Recent clinical trial data, particularly that of current and emerging JAK inhibitors, will be analyzed and clinical relevance debated. The faculty will relay best practices for shared decision making through patient education as well as strategies for engagement of the healthcare team. Upon completion of this discussion-based educational activity, learners will gain better insight into the emerging optimal monitoring and management techniques for patients with polycythemia vera.
Oncologists/hematologists, internists, nurse practitioners, nurses, and other healthcare providers responsible for the diagnosis, treatment or management of patients with polycythemia vera.
- Discuss the science of polycythemia vera, including diagnostic criteria, risk stratification and managing treatment resistance and/or intolerance
- Analyze clinical trial data of JAK inhibitors for the treatment of PV, as presented at ASH 2017
- Incorporate a shared decision-making approach with the healthcare team to develop individualized treatment plans to improve outcomes and overall quality of life in patients with PV
Disclosures of Conflict of Interest
It is the policy of AcademicCME that all faculty, instructors, and planners disclose real or apparent conflicts of interest relating to the topics of this educational activity.
The faculty reported the following financial relationships or relationships to products or devices they or their spouse/life partner have with commercial interests related to the content of this CME/CNE activity:
|Faculty||Relationship Identified With:|
|Ruben A. Mesa, MD (Chair)||Consultant/Advisor: AOP Orphan Pharmaceuticals; Novartis Pharmaceuticals CorporationGrant/Research Support: CTI BioPharma Corp.; Gilead Sciences, Inc.; Incyte Corporation|
|Naveen Pemmaraju, MD||Consultant/Advisor: Incyte Corporation; LFB; Novartis Pharmaceuticals Corporation; Stemline Therapeutics Inc.Grant/Research Support: AbbVie Inc.; Affymetrix; Cellectis; Novartis Pharmaceuticals Corporation; Samus Therapeutics, Inc.; Stemline Therapeutics Inc.|
|Srdan Verstovsek, MD, PhD||Nothing to disclose.|
Planners, Managers, Reviewers
Timothy Hayes, MD, PhD; Emma Boring; Nicole Brestowski and Kim Cheramie, MSN, RN-BC hereby state that they or their spouse/life partner do not have any financial relationships to products or devices with any commercial interests related to the content of this activity of any amount during the past 12 months.
AcademicCME is accredited by the Accreditation Council for Continuing Medical Education (ACCME) to provide continuing medical education for physicians.
AcademicCME is accredited as a provider of continuing nursing education by the American Nurses Credentialing Center’s Commission on Accreditation.
Credit Designation Statement
AcademicCME designates this enduring material for a maximum of 1.0 AMA PRA Category 1 Credit™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.
AcademicCME designates this enduring material for a maximum of 1.0 CNE contact hour (1.0 CNE pharmacotherapeutic contact hour).
This activity has been supported by an independent educational grant from Incyte Corporation.
Disclosure of Unlabeled Use
This educational activity may contain discussion of published and/or investigational uses of agents that are not indicated by the FDA. AcademicCME and Incyte Corporation do not recommend the use of any agent outside of the labeled indications.
Participants have an implied responsibility to use the newly acquired information to enhance patient outcomes and their own professional development. The information presented in this activity is not meant to serve as a guideline for patient management. Any procedures, medications, or other courses of diagnosis or treatment discussed or suggested in this activity should not be used by clinicians without evaluation of their patient’s conditions and possible contraindications on dangers in use, review of any applicable manufacturer’s product information, and comparison with recommendations of other authorities.
Method of Participation
In order to claim credit, participants must complete the following:
- Read the learning objectives, accreditation information and faculty disclosures at the beginning of this activity.
- Complete the Pre-Activity Questions.
- Read or Review the activity content.
- Complete the Post-Activity Test Questions and Evaluation.
- Healthcare providers who receive a grade of 70% or better on the Post-Activity Test Questions and who complete the Evaluation will receive a CME/CNE Certificate.
- All other participants who receive a grade of 70% or better on the Post-Activity Test Questions and who complete the Evaluation will receive a Certificate of Participation.
- Healthcare providers should claim only the credit commensurate with the extent of their participation in the activity.
- 60 minutes of participation = 1 CNE contact hour
CE Inquiries/Special Needs
For all CME/CNE inquiries or special needs, please contact firstname.lastname@example.org.